Prion diseases are fatal neurodegenerative and infectious disorders for which effective pharmacological tools are not yet available. This unmet challenge and the recently proposed interplay between prion diseases and Alzheimer's have led to a more urgent demand for new antiprion agents. Herein, we report the identification of a novel bifunctional diketopiperazine (DKP) derivative 1 d, which exhibits activity in the low micromolar range against prion replication in ScGT1 cells, while showing low cytotoxicity. Supported by properly addressed molecular modeling studies, we hypothesized that a planar conformation is the major determinant for activity in this class of compounds. Moreover, studies aimed at assessing the mechanism-of-action at the molecular level showed that 1 d might interact directly with recombinant prion protein (recPrP) to prevent its conversion to the pathogenic misfolded prion protein (PrP(Sc))-like form. This investigation suggests that DKP based antiprion compounds can serve as a promising lead scaffold in developing new drugs to combat prion diseases.

Discovery of a class of diketopiperazines as antiprion compounds / Bolognesi, Ml; AI TRAN, Hn; Staderini, M; Monaco, A; LÓPEZ COBEÑAS, A; Bongarzone, S; Biarnés, X; LÓPEZ ALVARADO, P; Cabezas, N; Caramelli, M; Carloni, P; Menéndez, Jc; Legname, Giuseppe. - In: CHEMMEDCHEM. - ISSN 1860-7179. - 5:8(2010), pp. 1324-1334. [10.1002/cmdc.201000133]

Discovery of a class of diketopiperazines as antiprion compounds

Legname, Giuseppe
2010-01-01

Abstract

Prion diseases are fatal neurodegenerative and infectious disorders for which effective pharmacological tools are not yet available. This unmet challenge and the recently proposed interplay between prion diseases and Alzheimer's have led to a more urgent demand for new antiprion agents. Herein, we report the identification of a novel bifunctional diketopiperazine (DKP) derivative 1 d, which exhibits activity in the low micromolar range against prion replication in ScGT1 cells, while showing low cytotoxicity. Supported by properly addressed molecular modeling studies, we hypothesized that a planar conformation is the major determinant for activity in this class of compounds. Moreover, studies aimed at assessing the mechanism-of-action at the molecular level showed that 1 d might interact directly with recombinant prion protein (recPrP) to prevent its conversion to the pathogenic misfolded prion protein (PrP(Sc))-like form. This investigation suggests that DKP based antiprion compounds can serve as a promising lead scaffold in developing new drugs to combat prion diseases.
2010
5
8
1324
1334
Bolognesi, Ml; AI TRAN, Hn; Staderini, M; Monaco, A; LÓPEZ COBEÑAS, A; Bongarzone, S; Biarnés, X; LÓPEZ ALVARADO, P; Cabezas, N; Caramelli, M; Carloni, P; Menéndez, Jc; Legname, Giuseppe
File in questo prodotto:
File Dimensione Formato  
Bolognesi_ChemMedChem_2010.pdf

non disponibili

Tipologia: Versione Editoriale (PDF)
Licenza: Non specificato
Dimensione 391.03 kB
Formato Adobe PDF
391.03 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11767/16849
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 42
  • ???jsp.display-item.citation.isi??? 44
social impact